Dentsply Sirona Q1 25 Earnings Conference Call At 8:30 AM ET
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2025
0mins
Should l Buy XRAY?
Source: NASDAQ.COM
Conference Call Announcement: Dentsply Sirona Inc will hold a conference call on May 8, 2025, at 8:30 AM ET to discuss their Q1 25 earnings results.
Webcast Access: The live webcast can be accessed through their investor relations website.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XRAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XRAY
Wall Street analysts forecast XRAY stock price to rise
16 Analyst Rating
2 Buy
13 Hold
1 Sell
Hold
Current: 12.810
Low
12.00
Averages
13.04
High
17.00
Current: 12.810
Low
12.00
Averages
13.04
High
17.00
About XRAY
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of XRAY's 52-Week High and Low Points
- Price Range Analysis: XRAY's stock has a 52-week low of $9.85 and a high of $19.27, with the last trade at $13.76, indicating stability within its trading range, which may attract investor interest.
- Technical Indicator Insight: The current stock price is above the 200-day moving average, suggesting a potential upward trend in the short term, which investors might consider as a buy signal.
- Market Sentiment Evaluation: Although the current price is below the 52-week high, it remains above the low, reflecting that market confidence in XRAY has not completely waned, potentially laying the groundwork for future rebounds.
- Investor Focus: XRAY's performance contrasts with nine other dividend stocks that recently crossed above their 200-day moving average, which may prompt investors to reassess its dividend yield potential.
See More
Halper Sadeh Investigates Dentsply Sirona Executives for Breach of Fiduciary Duties
- Legal Investigation Launched: Halper Sadeh LLC is investigating whether executives of Dentsply Sirona Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term shareholders of Dentsply may seek corporate governance reforms, fund recovery, or court-approved financial incentives aimed at enhancing company transparency and accountability.
- Legal Fee Arrangement: The firm will handle the case on a contingency fee basis, meaning shareholders will not be responsible for legal fees, thereby reducing the financial burden of participation.
- Importance of Investor Participation: Shareholder involvement can improve company policies and oversight mechanisms, enhancing shareholder value; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct.
See More
Dentsply Sirona (XRAY) Renews Dental Tech Agreement with Patterson Dental
- Partnership Continuation: Dentsply Sirona has renewed its U.S. dental technology distribution agreement with Patterson Dental, reaffirming their long-standing collaboration aimed at driving market growth through innovation.
- Product Portfolio Assurance: The new agreement ensures Patterson Dental customers will continue to access Dentsply Sirona's full range of dental technology solutions, including CEREC systems, Primescan intraoral scanners, and imaging systems, enhancing customer service experience.
- Accelerated Technology Integration: The partnership aims to accelerate the adoption of integrated and connected dental technologies, thereby improving practice efficiency and patient care quality, pushing the industry towards digital transformation.
- Positive Market Reaction: In pre-market trading on Nasdaq, Dentsply Sirona's stock rose by 0.74% to $12.22, reflecting market optimism regarding the renewal of this partnership.
See More
Benco Dental Expands Partnership with Dentsply Sirona to Offer Full Suite of Digital Dental Solutions
- Deepening Partnership: Benco Dental will start offering Dentsply Sirona's comprehensive digital dental technology solutions, including the CEREC system, aiming to enhance efficiency through an integrated ecosystem that improves patient care outcomes.
- Leading Technological Innovation: The new collaboration will enable Benco Dental's customers to more easily access cutting-edge digital solutions, leveraging Dentsply Sirona's industry-leading technologies to drive digital transformation and enhance service quality.
- Interactive Experience Centers: Benco Dental will create dedicated Dentsply Sirona experience areas in its CenterPoint showrooms in Los Angeles, Dallas, and between New York City and Philadelphia, providing interactive equipment testing and custom integration options to enhance customer experience.
- Market Leadership: This partnership not only solidifies Benco Dental's position as the largest family-owned dental company in the U.S. but also highlights its crucial role in advancing the digital transformation of the dental industry.
See More
Dentsply Sirona to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: Dentsply Sirona will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, where CEO Dan Scavilla will present the company's differentiated Connected Dentistry portfolio, highlighting its position in dental market trends.
- Strategic Update: During the presentation, Dentsply Sirona will share progress on its return-to-growth strategy, aiming to bolster investor confidence in the company's future and showcase its leadership in the industry.
- Online Access: Investors and interested parties can access a live audio webcast and replay through the Investors section of Dentsply Sirona's website, ensuring transparency and timely communication of information.
- Industry Leader: As the world's largest diversified manufacturer of professional dental products and technologies, Dentsply Sirona boasts over a century of innovation, committed to delivering high-quality dental solutions that further solidify its competitive advantage in the global market.
See More
Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades: Morgan Stanley upgraded Accenture Plc from Equal-Weight to Overweight, raising its price target from $271 to $320, while Cantor Fitzgerald upgraded Microchip Technology Inc from Neutral to Overweight with a target increase from $65 to $85.
Price Target Increases: Wedbush raised Tyra Biosciences Inc's target from $30 to $37, and Chardan Capital increased Palvella Therapeutics Inc's target from $110 to $174, both maintaining positive ratings.
Mixed Ratings: Baird cut Dentsply Sirona Inc's price target from $14 to $12 while maintaining a Neutral rating, contrasting with their upgrade of Tandem Diabetes Care Inc from Neutral to Outperform with a target increase from $18 to $30.
Other Notable Changes: Goldman Sachs upgraded Rockwell Automation Inc from Sell to Neutral, raising its target from $329 to $448, while Needham increased SI-Bone Inc's target from $24 to $27, maintaining a Buy rating.
See More
Analysis of XRAY's 52-Week High and Low Points
- Price Range Analysis: XRAY's stock has a 52-week low of $9.85 and a high of $19.27, with the last trade at $13.76, indicating stability within its trading range, which may attract investor interest.
- Technical Indicator Insight: The current stock price is above the 200-day moving average, suggesting a potential upward trend in the short term, which investors might consider as a buy signal.
- Market Sentiment Evaluation: Although the current price is below the 52-week high, it remains above the low, reflecting that market confidence in XRAY has not completely waned, potentially laying the groundwork for future rebounds.
- Investor Focus: XRAY's performance contrasts with nine other dividend stocks that recently crossed above their 200-day moving average, which may prompt investors to reassess its dividend yield potential.
See More
Halper Sadeh Investigates Dentsply Sirona Executives for Breach of Fiduciary Duties
- Legal Investigation Launched: Halper Sadeh LLC is investigating whether executives of Dentsply Sirona Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term shareholders of Dentsply may seek corporate governance reforms, fund recovery, or court-approved financial incentives aimed at enhancing company transparency and accountability.
- Legal Fee Arrangement: The firm will handle the case on a contingency fee basis, meaning shareholders will not be responsible for legal fees, thereby reducing the financial burden of participation.
- Importance of Investor Participation: Shareholder involvement can improve company policies and oversight mechanisms, enhancing shareholder value; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct.
See More
Dentsply Sirona (XRAY) Renews Dental Tech Agreement with Patterson Dental
- Partnership Continuation: Dentsply Sirona has renewed its U.S. dental technology distribution agreement with Patterson Dental, reaffirming their long-standing collaboration aimed at driving market growth through innovation.
- Product Portfolio Assurance: The new agreement ensures Patterson Dental customers will continue to access Dentsply Sirona's full range of dental technology solutions, including CEREC systems, Primescan intraoral scanners, and imaging systems, enhancing customer service experience.
- Accelerated Technology Integration: The partnership aims to accelerate the adoption of integrated and connected dental technologies, thereby improving practice efficiency and patient care quality, pushing the industry towards digital transformation.
- Positive Market Reaction: In pre-market trading on Nasdaq, Dentsply Sirona's stock rose by 0.74% to $12.22, reflecting market optimism regarding the renewal of this partnership.
See More
Benco Dental Expands Partnership with Dentsply Sirona to Offer Full Suite of Digital Dental Solutions
- Deepening Partnership: Benco Dental will start offering Dentsply Sirona's comprehensive digital dental technology solutions, including the CEREC system, aiming to enhance efficiency through an integrated ecosystem that improves patient care outcomes.
- Leading Technological Innovation: The new collaboration will enable Benco Dental's customers to more easily access cutting-edge digital solutions, leveraging Dentsply Sirona's industry-leading technologies to drive digital transformation and enhance service quality.
- Interactive Experience Centers: Benco Dental will create dedicated Dentsply Sirona experience areas in its CenterPoint showrooms in Los Angeles, Dallas, and between New York City and Philadelphia, providing interactive equipment testing and custom integration options to enhance customer experience.
- Market Leadership: This partnership not only solidifies Benco Dental's position as the largest family-owned dental company in the U.S. but also highlights its crucial role in advancing the digital transformation of the dental industry.
See More
Dentsply Sirona to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: Dentsply Sirona will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, where CEO Dan Scavilla will present the company's differentiated Connected Dentistry portfolio, highlighting its position in dental market trends.
- Strategic Update: During the presentation, Dentsply Sirona will share progress on its return-to-growth strategy, aiming to bolster investor confidence in the company's future and showcase its leadership in the industry.
- Online Access: Investors and interested parties can access a live audio webcast and replay through the Investors section of Dentsply Sirona's website, ensuring transparency and timely communication of information.
- Industry Leader: As the world's largest diversified manufacturer of professional dental products and technologies, Dentsply Sirona boasts over a century of innovation, committed to delivering high-quality dental solutions that further solidify its competitive advantage in the global market.
See More
Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades: Morgan Stanley upgraded Accenture Plc from Equal-Weight to Overweight, raising its price target from $271 to $320, while Cantor Fitzgerald upgraded Microchip Technology Inc from Neutral to Overweight with a target increase from $65 to $85.
Price Target Increases: Wedbush raised Tyra Biosciences Inc's target from $30 to $37, and Chardan Capital increased Palvella Therapeutics Inc's target from $110 to $174, both maintaining positive ratings.
Mixed Ratings: Baird cut Dentsply Sirona Inc's price target from $14 to $12 while maintaining a Neutral rating, contrasting with their upgrade of Tandem Diabetes Care Inc from Neutral to Outperform with a target increase from $18 to $30.
Other Notable Changes: Goldman Sachs upgraded Rockwell Automation Inc from Sell to Neutral, raising its target from $329 to $448, while Needham increased SI-Bone Inc's target from $24 to $27, maintaining a Buy rating.
See More
